Triple
T10292145
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | bortezomib |
E241388
|
entity |
| Predicate | oftenUsedWith |
P4791
|
FINISHED |
| Object | melphalan |
E261829
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: melphalan | Statement: [bortezomib, oftenUsedWith, melphalan]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: melphalan Context triple: [bortezomib, oftenUsedWith, melphalan]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
cyclophosphamide
chosen
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
C.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381aaafc08190af475ef58dc16aba |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4d2d35f048190a215493acdf1f718 |
completed | April 7, 2026, 9:48 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d6f85dcbac8190a2ac66354010e328 |
completed | April 9, 2026, 12:52 a.m. |
Created at: April 6, 2026, 11:42 a.m.